GlucoTrack, Inc. cash flow to debt ratio of -46.18K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

GlucoTrack, Inc.'s free cash flow has decreased 21.77% from $-12.59M last year to $-15.34M, signaling decreasing performance

GlucoTrack, Inc.'s debt to equity ratio is -0.03, signaling that the company spent its equity and risk bankruptcy.

GlucoTrack, Inc.'s debt to equity ratio is -0.03, signaling that the company spent its equity and risk bankruptcy.

GlucoTrack, Inc. has a net cash position, so leverage is healthy.

GlucoTrack, Inc.'s interest coverage ratio is -65.42, which means that the company struggles to meet interest obligations, signaling financial risk.

GlucoTrack, Inc. has insufficient data to evaluate this check.

GlucoTrack, Inc.'s short-term assets of $7.67M exceed its short-term liabilities of $4.77M

GlucoTrack, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

GlucoTrack, Inc.'s return on equity of -581.98%, is lower than 15.00%, indicating bad performance

GlucoTrack, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

GlucoTrack, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

GlucoTrack, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

GlucoTrack, Inc. has negative free cash flow, indicating cash burn

GlucoTrack, Inc.'s yearly earnings has increased -14.20% since last year from $-22.60M to $-19.39M, signaling increasing performance

GlucoTrack, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC 1.38K% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

GlucoTrack, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

GlucoTrack, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

GlucoTrack, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

GlucoTrack, Inc. has insufficient data to evaluate this check.

GlucoTrack, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

GlucoTrack, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

GlucoTrack, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

GlucoTrack, Inc. has insufficient data to evaluate this check.

GlucoTrack, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

GlucoTrack, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

GlucoTrack, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue